Oculis Appoints Katie Kazem as Chief Legal Officer

Core Insights - Oculis Holding AG has appointed Katie Kazem as Chief Legal Officer, enhancing its legal, compliance, and corporate governance functions [1][2] - The company is advancing its product Privosegtor into the PIONEER program and is expecting topline results for OCS-01 eye drops in diabetic macular edema (DME) in Q2 [2] - Oculis has a differentiated late-stage clinical pipeline, including three core product candidates: Privosegtor, OCS-01, and Licaminlimab [4] Company Overview - Oculis is a global biopharmaceutical company focused on innovations in neuro-ophthalmology and ophthalmology [4] - The company is headquartered in Switzerland and has operations in the U.S. and Iceland [4] - Oculis is supported by leading international healthcare investors and led by an experienced management team [4] Product Pipeline - Privosegtor is a neuroprotective candidate in the PIONEER program aimed at treating optic neuropathies [4] - OCS-01 is in pivotal registration studies to become the first non-invasive topical treatment for DME [4] - Licaminlimab is a novel topical anti-TNFα in Phase 2, focusing on precision medicine for dry eye disease [4] Leadership and Expertise - Katie Kazem brings over 15 years of experience in corporate and securities law, particularly in life sciences [2][5] - She has a strong background in advising on IPOs, capital raising, M&A, and regulatory compliance [2][5] - Kazem has previously served as external legal counsel to Oculis since its NASDAQ listing in March 2023 [2]